These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37951998)

  • 21. Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial.
    Geng LN; Bonilla H; Hedlin H; Jacobson KB; Tian L; Jagannathan P; Yang PC; Subramanian AK; Liang JW; Shen S; Deng Y; Shaw BJ; Botzheim B; Desai M; Pathak D; Jazayeri Y; Thai D; O'Donnell A; Mohaptra S; Leang Z; Reynolds GZM; Brooks EF; Bhatt AS; Shafer RW; Miglis MG; Quach T; Tiwari A; Banerjee A; Lopez RN; De Jesus M; Charnas LR; Utz PJ; Singh U
    JAMA Intern Med; 2024 Sep; 184(9):1024-1034. PubMed ID: 38848477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
    Ioannou GN; Berry K; Rajeevan N; Li Y; Mutalik P; Yan L; Bui D; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Bajema KL
    Ann Intern Med; 2023 Nov; 176(11):1486-1497. PubMed ID: 37903369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk.
    Paraskevis D; Gkova M; Mellou K; Gerolymatos G; Psalida N; Gkolfinopoulou K; Kostaki EG; Loukides S; Kotanidou A; Skoutelis A; Thiraios E; Saroglou G; Zografopoulos D; Filippou D; Mossialos E; Zaoutis T; Gaga M; Tsiodras S; Antoniadou A
    J Infect Dis; 2023 Dec; 228(12):1667-1674. PubMed ID: 37565522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
    Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
    Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina.
    Henderson HI; Wohl DA; Fischer WA; Bartelt LA; van Duin D; Agil DM; Browne LE; Li KP; Moy A; Eron JJ; Napravnik S
    J Antimicrob Chemother; 2024 Apr; 79(4):859-867. PubMed ID: 38380946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
    Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
    JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Effectiveness of Nirmatrelvir-Ritonavir and Its Acceptability in High-Risk COVID-19 Patients.
    Kim MK; Lee KS; Ham SY; Choi YY; Lee E; Lee S; Lee B; Jeon J; Chin B; Kim Y; Kim G; Jang HC; Choi JP; Park SW
    J Korean Med Sci; 2023 Sep; 38(35):e272. PubMed ID: 37667578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study.
    Luo W; Li KY; Dai C; Zhu W; Lin J; Lu F; Chen Q; Wang W; Zhuang Q; Lin Y
    Infection; 2024 Aug; 52(4):1519-1525. PubMed ID: 38652225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
    Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
    Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
    Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ
    J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.
    Salmanton-García J; Marchesi F; Koehler P; Weinbergerová B; Čolović N; Falces-Romero I; Buquicchio C; Farina F; van Praet J; Biernat MM; Itri F; Prezioso L; Tascini C; Vena A; Romano A; Delia M; Dávila-Valls J; Martín-Pérez S; Lavilla-Rubira E; Adžić-Vukičević T; García-Bordallo D; López-García A; Criscuolo M; Petzer V; Fracchiolla NS; Espigado I; Sili U; Meers S; Erben N; Cattaneo C; Tragiannidis A; Gavriilaki E; Schönlein M; Mitrovic M; Pantic N; Merelli M; Labrador J; Hernández-Rivas JÁ; Glenthøj A; Fouquet G; Del Principe MI; Dargenio M; Calbacho M; Besson C; Kohn M; Gräfe S; Hersby DS; Arellano E; Çolak GM; Wolf D; Marchetti M; Nordlander A; Blennow O; Cordoba R; Mišković B; Mladenović M; Bavastro M; Limongelli A; Rahimli L; Pagano L; Cornely OA
    Int J Antimicrob Agents; 2023 Oct; 62(4):106952. PubMed ID: 37582478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
    Wong CKH; Lau KTK; Au ICH; Lau EHY; Poon LLM; Hung IFN; Cowling BJ; Leung GM
    Lancet Infect Dis; 2023 Jun; 23(6):683-695. PubMed ID: 36796397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation.
    Wong CKH; Lau KTK; Au ICH; Chan SHS; Lau EHY; Cowling BJ; Leung GM
    Nat Commun; 2024 Jun; 15(1):4917. PubMed ID: 38851796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nirmatrelvir Plus Ritonavir: First Approval.
    Lamb YN
    Drugs; 2022 Apr; 82(5):585-591. PubMed ID: 35305258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.
    Han X; Gao D; Li C; Yuan X; Cui J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Zhao D; Zhang X; Han X; Wang B; Zhang T; Xie W; Xie L
    BMC Infect Dis; 2024 Jan; 24(1):57. PubMed ID: 38191304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection.
    Chuang MH; Wu JY; Liu TH; Hsu WH; Tsai YW; Huang PY; Lai CC
    J Med Virol; 2023 Apr; 95(4):e28750. PubMed ID: 37185834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir-Ritonavir for COVID-19 in an interdisciplinary community clinic.
    Leung V; Gill S; Llanes A; Khawaja A; Stagg A; McCready J; Jacubovich M; Ho G; Powis J; Kandel C
    PLoS One; 2023; 18(10):e0293302. PubMed ID: 37856531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of Sanhan Huashi granules versus nirmatrelvir-ritonavir in adult patients with COVID-19: A randomized, open-label, multicenter trial.
    Zou X; Chang K; Fan G; Zheng H; Shen H; Tang L; Yang Y; Wang Y; Zhao L; Lv H; Zhou X; Shen X; Chen L; Tong X; Cao B;
    Sci Bull (Beijing); 2024 Jun; 69(12):1954-1963. PubMed ID: 38749859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.